Ignite Creation Date:
2025-12-25 @ 4:15 AM
Ignite Modification Date:
2026-03-04 @ 1:38 PM
Study NCT ID:
NCT01646320
Status:
COMPLETED
Last Update Posted:
2016-06-22
First Post:
2012-07-18
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2012-09
Start Date Type:
None
Primary Completion Date:
2014-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2015-02
Completion Date Type:
ACTUAL
First Submit Date:
2012-07-18
First Submit QC Date:
None
Study First Post Date:
2012-07-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-03-09
Results First Submit QC Date:
None
Results First Post Date:
2016-04-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2016-05-18
Last Update Post Date:
2016-06-22
Last Update Post Date Type:
ESTIMATED